(Q44444416)

3 December 2017

title

Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects (English)

1 reference

3 December 2017

Combined scintigraphic and pharmacokinetic investigation of enteric‐coated mesalazine micropellets in healthy subjects (English)

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

3 January 2024

1 reference

I. R. Wilding

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752352

3 January 2024

C. Behrens

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752352

3 January 2024

S. J. Tardif

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752352

3 January 2024

H. Wray

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752352

3 January 2024

P. Bias

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752352

3 January 2024

W. Albrecht

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752352

3 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

3 December 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2036.2003.01558.x

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.2003.01558.x

3 January 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Alimentary Pharmacology & Therapeutics

3 January 2024

published in

1 reference

3 December 2017

volume

17

1 reference

3 December 2017

issue

9

1 reference

3 December 2017

page(s)

1153-1162

1 reference

Mechanism of action of 5-aminosalicylic acid and its derivatives

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01558.X

Absorption of 5-aminosalicylic acid from colon and rectum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01558.X

Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01558.X

Absorption, metabolism, and excretion of salicylazosulfapyridine in man

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease

3 January 2024

2

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Pharmacokinetic considerations in the treatment of inflammatory bowel disease

3 January 2024

3

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

3 January 2024

Crohn's disease

4

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

3 January 2024

Ulcerative colitis

5

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

3 January 2024

6

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease

3 January 2024

9

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations

3 January 2024

12

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease

3 January 2024

15

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Gruppo Italiano per lo Studio del Colon e del Retto

3 January 2024

16

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis

3 January 2024

17

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Delivery and fate of oral mesalamine microgranules within the human small intestine

3 January 2024

18

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract

3 January 2024

20

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

3 January 2024

21

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease

3 January 2024

22

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

3 January 2024

24

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Measurement of gastrointestinal pH profiles in normal ambulant human subjects

3 January 2024

26

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

pH-profile and regional transit times of the normal gut measured by a radiotelemetry device

3 January 2024

27

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Coated dosage forms for colon-specific drug delivery

3 January 2024

28

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

In vivo evaluation of dosage forms: application of gamma scintigraphy to non-enteral routes of administration

3 January 2024

30

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects

3 January 2024

31

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations

3 January 2024

32

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Transit of pharmaceutical dosage forms through the small intestine

3 January 2024

33

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

Bioequivalence testing for locally acting gastrointestinal products: what role for gamma scintigraphy?

3 January 2024

34

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01558.X

3 January 2024

Identifiers

1 reference

3 December 2017

1 reference